To the best of our knowledge, we only found 4 studies which reported a total of 5 cumulative cases (Table 2) using pembrolizumab as the single PD-1 inhibitor in the treatment of chemo-resistant choriocarcinoma (4, 6, 19, 20). This evidence concerns the gene PDCD1 and choriocarcinoma.